Use of Perioperative Chemotherapy in Colorectal Cancer Metastatic to the Liver

Overview

Journal Gastroenterol Rep (Oxf)

Specialty Gastroenterology

Date 2019 Nov 6

PMID 31687149

Citations 8

Authors

Lynn K Symonds

Stacey A Cohen

Affiliations

Soon will be listed here.

Abstract

A curative-intent approach may improve survival in carefully selected patients with oligometastatic colorectal cancer. Aggressive treatments are most frequently administered to patients with isolated liver metastasis, though they may be judiciously considered for other sites of metastasis. To be considered for curative intent with surgery, patients must have disease that can be definitively treated while leaving a sufficient functional liver remnant. Neoadjuvant chemotherapy may be used for upfront resectable disease as a test of tumor biology and/or for upfront unresectable disease to increase the likelihood of resectability (so-called 'conversion' chemotherapy). While conversion chemotherapy in this setting aims to improve survival, the choice of a regimen remains a complex and highly individualized decision. In this review, we discuss the role of status, primary site, sidedness, and other clinical features that affect chemotherapy treatment selection as well as key factors of patients that guide individualized patient-treatment recommendations for colorectal-cancer patients being considered for definitive treatment with metastasectomy.

Citing Articles

Expert consensus on the optimal management of BRAF-mutant metastatic colorectal cancer in the Asia-Pacific region.

Piercey O, Chantrill L, Hsu H, Ma B, Price T, Tan I Asia Pac J Clin Oncol. 2024; 21(1):31-45.

PMID: 39456063 PMC: 11733838. DOI: 10.1111/ajco.14132.

FOLFOXIRI plus cetuximab as conversion therapy for unresectable RAS/BRAF wild-type left-sided colorectal cancer with liver-limited metastases: a prospective dual-center pilot study.

Yang W, Chen D, Niu Y, Wu G, Huang Z, Bi X Front Oncol. 2024; 14:1375906.

PMID: 38638850 PMC: 11024419. DOI: 10.3389/fonc.2024.1375906.

Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study.

Liu X, Ou K, Ma X, Gao L, Wang Q, Zhang H BMC Cancer. 2022; 22(1):807.

PMID: 35864467 PMC: 9306070. DOI: 10.1186/s12885-022-09889-3.

Safety and feasibility of neoadjuvant chemotherapy as a surgical bridge for acute left-sided malignant colorectal obstruction: a retrospective study.

Zhang J, Deng J, Hu J, Zhong Q, Li J, Su M BMC Cancer. 2022; 22(1):806.

PMID: 35864459 PMC: 9306149. DOI: 10.1186/s12885-022-09906-5.

Casein Kinase-1-Alpha Inhibitor (D4476) Sensitizes Microsatellite Instable Colorectal Cancer Cells to 5-Fluorouracil via Authophagy Flux Inhibition.

Siri M, Behrouj H, Dastghaib S, Zamani M, Likus W, Rezaie S Arch Immunol Ther Exp (Warsz). 2021; 69(1):26.

PMID: 34536148 PMC: 8449776. DOI: 10.1007/s00005-021-00629-2.

References

Kanas G, Taylor A, Primrose J, Langeberg W, Kelsh M, Mowat F . Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012; 4:283-301. PMC: 3496330. DOI: 10.2147/CLEP.S34285. View

Steele Jr G, Bleday R, Mayer R, Lindblad A, Petrelli N, Weaver D . A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol. 1991; 9(7):1105-12. DOI: 10.1200/JCO.1991.9.7.1105. View

Steele Jr G, Ravikumar T . Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg. 1989; 210(2):127-38. PMC: 1357818. DOI: 10.1097/00000658-198908000-00001. View

Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier A . Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006; 244(2):254-9. PMC: 1602156. DOI: 10.1097/01.sla.0000217629.94941.cf. View

Cummings L, Payes J, Cooper G . Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer. 2007; 109(4):718-26. DOI: 10.1002/cncr.22448. View

Saltz L, Niedzwiecki D, Hollis D, Goldberg R, Hantel A, Thomas J . Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007; 25(23):3456-61. DOI: 10.1200/JCO.2007.11.2144. View

Pozzo C, Basso M, Cassano A, Quirino M, Schinzari G, Trigila N . Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004; 15(6):933-9. DOI: 10.1093/annonc/mdh217. View

Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F . Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol. 1999; 10(6):663-9. DOI: 10.1023/a:1008347829017. View

Primrose J, Falk S, Finch-Jones M, Valle J, OReilly D, Siriwardena A . Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol. 2014; 15(6):601-11. DOI: 10.1016/S1470-2045(14)70105-6. View

10.

Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C . Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo.... J Clin Oncol. 2007; 25(13):1670-6. DOI: 10.1200/JCO.2006.09.0928. View

11.

Adam R, Hoti E, Bredt L . [Oncosurgical strategies for metastatic liver cancer]. Cir Esp. 2010; 89(1):10-9. DOI: 10.1016/j.ciresp.2010.10.007. View

12.

Adams R, Aloia T, Loyer E, Pawlik T, Taouli B, Vauthey J . Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford). 2013; 15(2):91-103. PMC: 3719914. DOI: 10.1111/j.1477-2574.2012.00557.x. View

13.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

14.

Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B . Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?. Ann Surg. 2004; 240(6):1052-61. PMC: 1356520. DOI: 10.1097/01.sla.0000145964.08365.01. View

15.

Venook A, Niedzwiecki D, Lenz H, Innocenti F, Fruth B, Meyerhardt J . Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017; 317(23):2392-2401. PMC: 5545896. DOI: 10.1001/jama.2017.7105. View

16.

Peeters M, Price T, Cervantes A, Sobrero A, Ducreux M, Hotko Y . Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010; 28(31):4706-13. DOI: 10.1200/JCO.2009.27.6055. View

17.

Pulitano C, Bodingbauer M, Aldrighetti L, Jong M, Castillo F, Schulick R . Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. Ann Surg Oncol. 2010; 18(5):1380-8. DOI: 10.1245/s10434-010-1459-4. View

18.

Fowler W, Eisenberg B, Hoffman J . Hepatic resection following systemic chemotherapy for metastatic colorectal carcinoma. J Surg Oncol. 1992; 51(2):122-5. DOI: 10.1002/jso.2930510212. View

19.

Adam R, De Gramont A, Figueras J, Kokudo N, Kunstlinger F, Loyer E . Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev. 2015; 41(9):729-41. DOI: 10.1016/j.ctrv.2015.06.006. View

20.

Nordlinger B, Sorbye H, Glimelius B, Poston G, Schlag P, Rougier P . Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013; 14(12):1208-15. DOI: 10.1016/S1470-2045(13)70447-9. View